Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers May 28, 2017
Pharmacy Choice - News - Over-the-Counter Drugs - May 28, 2017

Pharmacy News

 Over-the-Counter Drugs
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

4/28/17 - Allergan Teams Up With Media Mogul Wendy Williams to Debut the Patient Empowerment Campaign - Toilet Talk
By a News Reporter-Staff News Editor at Health& Medicine Week- Allergan plc, a global pharmaceutical company and leader in developing best-in-class treatment options for patients, has partnered with the American Gastroenterological Association, to announce the launch of Toilet TalkSM in celebration of IBS Awareness Month. At the center of this mu
4/28/17 - BioPharmX Announces Closing of $5.0 Million Offering
BioPharmX Corporation, a specialty pharmaceutical company developing products for the dermatology market, announced the closing of a registered direct offering following its entry into securities purchase agreements with certain existing institutional investors for the purchase and sale of 6,410,258 shares of common stock at a price of $0.78 per.
4/28/17 - GNW-News: Novartis receives FDA approval for Rydapt in newly diagnosed FLT3-mutated acute myeloid leukemia (AML) and three types of systemic mastocytosis (SM) (english)
Novartis receives FDA approval for Rydapt in newly diagnosed FLT3-mutated acute myeloid leukemia and three types of systemic mastocytosis. Novartis International AG/ Novartis receives FDA approval for Rydapt in newly diagnosed FLT3-mutated acute myeloid leukemia and three types of systemic mastocytosis. Processed and transmitted by Nasdaq...
4/28/17 - Novartis receives FDA approval for Rydapt in newly diagnosed FLT3-mutated acute myeloid leukemia (AML) and three types of systemic mastocytosis (SM)
Novartis announced today the US Food and Drug Administration has approved Rydapt for two indications. The first indication is for the treatment of acute myeloid leukemia in newly diagnosed patients who are FMS-like tyrosine kinase 3 mutation-positive, as detected by an FDA- approved test, in combination with chemotherapy 3. This approval follo
4/28/17 - Ridgecrest Herbals to Phase out Homeopathics in Their Formulas, Beginning with ClearLungs Extra Strength
Traditionally, the FTC has not significantly regulated either advertising or labels of homeopathic drugs, leaving the FDA to act as the primary regulatory agency for homeopathy. For many years, the FDA has been opposed to combinations of homeopathics with other products such as herbs, because homeopathics are regulated as drugs and herbs are genera
4/28/17 - Sen. Hassan Votes Against Gottlieb's Nomination for FDA Commissioner in HELP Committee
Maggie Hassan, D- N.H., issued the following statement after voting in opposition to the nomination of President Trump's nominee for FDA Commissioner, Scott Gottlieb, in the Senate Health, Education, Labor and Pensions Committee:. "I am especially concerned about Dr. Gottlieb's connections to a particular company that makes fentanyl products, and
4/27/17 - Bausch + Lomb Receives 510 Clearance from FDA for Vitesse, the Only Hypersonic, Open Port Vitrectomy System
Release date- 26042017- BRIDGEWATER, NJ- Bausch+ Lomb, a leading global eye health company, today announced that it has received 510 clearance from the U.S. Food and Drug Administration for Vitesse, the first and only hypersonic, 100% open port vitrectomy system. 'The ongoing development of Vitesse is an exciting example of Bausch+ Lomb's commitmen
4/27/17 - Bausch + Lomb Receives 510(k) Clearance from FDA for Vitesse, the Only Hypersonic, Open Port Vitrectomy System
Release date- 26042017- BRIDGEWATER, NJ- Bausch+ Lomb, a leading global eye health company, today announced that it has received 510 clearance from the U.S. Food and Drug Administration for Vitesse, the first and only hypersonic, 100% open port vitrectomy system. 'The ongoing development of Vitesse is an exciting example of Bausch+ Lomb's commitmen
4/27/17 - Ipsen Reports Strong First Quarter 2017 Sales Growth of 19,1%1
Ipsen, a global specialty-driven pharmaceutical group, today announced sales for the first quarter of 2017.. Commenting on the first quarter 2017 performance, David Meek, Chief Executive Officer of Ipsen said: In the first quarter, Specialty Care continued to drive remarkable organic top-line growth for Ipsen, led by the outstanding performance
4/27/17 - Kasten Merger and Stock Restructure
Kasten, Inc. has completed its acquisition through the merger of DAKOTA Life Sciences, now a wholly owned subsidiary of Kasten, Inc. The cashless transaction was accomplished by a 42 million share block issuance to Thru Pharma, LLC, dba DAKOTA Life Sciences. Concurrent with this merger, Kasten, Inc. also reduced the number of shares outstanding fro
4/27/17 - Novo Nordisk Receives FDA Approval of Saxenda (liraglutide) injection 3 mg Label Update Including Long-Term Safety and Efficacy Data from 3-Year Trial
Novo Nordisk today announced that the US Food and Drug Administration approved an updated product label for Saxenda injection 3 mg, including data showing that approximately half of patients on Saxenda who lost more than or equal to 5% of their weight after 56 weeks maintained their weight loss for 3 years. "We are pleased by the FDA's app
4/27/17 - PROVECTUS BIOPHARMACEUTICALS, INC. (OTCMKTS:PVCT) Files An 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
PROVECTUS BIOPHARMACEUTICALS, INC. (OTCMKTS:PVCT) Files An 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of ListingItem3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On April21, 2017, the NYSE MKT LLC (the NYSE MKT) filed a Form 25 w
4/27/17 - Senator Hassan Votes Against Dr. Scott Gottlieb's Nomination for FDA Commissioner in HELP Committee
WASHINGTON- Today, Senator Maggie Hassan released the following statement after voting in opposition to the nomination of President Trump's nominee for FDA Commissioner, Dr. I am especially concerned about Dr. Gottlieb's connections to a particular company that makes fentanyl products, and about his opposition to the creation of one of the FDA's ke
4/27/17 - Technical Reports on Generic Drugs Stocks Mylan, Allergan, Horizon Pharma, and Rigel Pharma
Stock-Callers.com has initiated coverage on select Generic Drugs stocks, particularly: Mylan N.V., Allergan PLC, Horizon Pharma PLC, and Rigel Pharmaceuticals Inc.. Hatfield, the UK- based Mylan N.V.' s shares gained 1.60%, closing Wednesday's trading session at $37.44. On April 17 th, 2017, research firm RBC Capital Markets reiterated its' Sector
4/26/17 - Bausch + Lomb Receives 510(k) Clearance From FDA For Vitesse?, The First And Only Hypersonic, Open-Port Vitrectomy System
Valeant Pharmaceuticals International, Inc.' s wholly owned subsidiary, Bausch+ Lomb, today announced it has received 510 clearance from the U.S. Food and Drug Administration for Vitesse?, the first and only hypersonic device for vitreous removal, which uses a novel, single-needle design and a continuously open-port system. "The successful cle
4/26/17 - BioPharmX Announces $5.0 Million Offering
BioPharmX Corporation, a specialty pharmaceutical company developing products for the dermatology market, announced that it is has entered into securities purchase agreements with certain existing institutional investors for the purchase and sale of 6,410,258 shares of common stock at a price of $0.78 per share with 50% warrant coverage in a...
4/26/17 - GSK posts revenue gains across the board [The News & Observer (Raleigh, N.C.)]
April 26 Pharmaceutical giant GlaxoSmithKline posted revenue gains in all three of its major businesses as new CEO Emma Walmsley noted that selling pharmaceuticals, vaccines and consumer products is an advantage given the drug industry's volatility. Walmsley, who was named CEO in September and took over the company's reins this month, was quoted
4/25/17 - Credence Research: Global In-vitro Diagnostics Market research report 2017-2022
According to the latest report published by Credence Research, Inc. "Global In-vitro Diagnostics Market- Growth, Opportunities, Competitive Analysis, and Forecast, 2016- 2022," the in-vitro diagnostics market was valued at USD 60,468.7 Mn in 2015, and is expected to reach USD 81,345.1 Mn by 2022, expanding at a CAGR of 4.2% from 2016 to 2022..
4/25/17 - Orexigen Therapeutics Announces New Drug Submission for Contrave in Canada
Orexigen Therapeutics, Inc., a biopharmaceutical company helping to improve the health and lives of patients struggling with weight loss, today announced that Health Canada has completed its screening phase and accepted for review a New Drug Submission for marketing approval of Contrave . The regulatory submission was filed by Valeant Canada, a
4/25/17 - PhaseRx Receives Positive Opinion for Orphan Drug Designation for PRX-OTC from European Medicines Agency
PhaseRx, Inc., a biopharmaceutical company developing mRNA treatments for life-threatening inherited liver diseases in children, today announced that the European Medicines Agency's Committee for Orphan Medicinal Products has issued a positive opinion recommending orphan medicinal product designation for PRX-OTC for the treatment of ornithine...
4/25/17 - ProSolus Seeks Higher Utilization of Transdermal Drug Delivery Technology
ProSolus, Inc. is doubling down on its efforts to expand the utilization of transdermal drug delivery technologies. Today Mission Pharmacal Company and ProSolus announced the expanded manufacturing capabilities of ProSolus and an increased emphasis on the company's overall commercialization efforts. Juan Mantelle, ProSolus Chief Operating Officer..
4/25/17 - Regeneron and Sanofi Announce FDA Approval of a New Once-Monthly Dosing Option for Praluent (alirocumab) Injection
TARRYTOWN, N.Y. and BRIDGEWATER, N.J., April 25, 2017/ PRNewswire/ Regeneron Pharmaceuticals, Inc. and Sanofi today announced that the U.S. Food and Drug Administration approved the companies' new supplemental Biologics License Application for a once-monthly, 300 mg dose of Praluent Injection for the treatment of adults with high low-density l
4/25/17 - Research Reports Initiation on Drug Makers Stocks Depomed, Pernix Therapeutics, Orexigen Therapeutics, and United Therapeutics
Four equities have been lined up for review this morning, and they are: Depomed Inc., Pernix Therapeutics Holdings Inc., Orexigen Therapeutics Inc., and United Therapeutics Corp.. On Monday, shares in Newark, California headquartered Depomed Inc. recorded a trading volume of 1.14 million shares, and ended the session 1.76% higher at $11.57.
4/25/17 - Sanofi and Regeneron Announce FDA Approval of a New Once-Monthly Dosing Option for Praluent (alirocumab) Injection
BRIDGEWATER, N.J. and TARRYTOWN, N.Y., April 25, 2017/ PRNewswire/ Sanofi and Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration approved the companies' new supplemental Biologics License Application for a once-monthly, 300 mg dose of Praluent Injection for the treatment of adults with high low-density l
4/24/17 - BioMarin Announces Kuvan sapropterin dihydrochloride Patent Challenge Settlement
By a News Reporter-Staff News Editor at Pharma Business Week- BioMarin Pharmaceutical Inc., announced that it has entered into a settlement agreement with Par Pharmaceutical that resolves patent litigation in the United States related to BioMarin's Kuvan 100 mg oral tablets and powder for oral solution in 100 mg packets. Under the terms of the
Articles(s): 1 - 25 of 250     Next >>     Go To Page:


© 2017 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Legal & Practical Issues in Compounding Pharmacy
This lesson is supported by:
RxSchool
Telepharmacy- Remote Delivery of Pharmacy Services
This lesson is supported by:
RxSchool
Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
RxSchool
Drug Therapy Management Series Part III: Geriatric Disorders
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415